

Chapter 41

Cutaneous Reactions to Drugs

Neil H. Shear & Sandra R. Knowles

REFERENCES

1. Lazarou J, Pomeranz B, Corey P: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. *JAMA* **279**:1200-1205, 1998
2. Bigby M: Rates of cutaneous reactions to drugs. *Arch Dermatol* **137**:765-770, 2001
3. Segal A et al: Cutaneous reactions to drugs in children. *Pediatrics* **120**:e1082-e1096, 2007
4. Batchelor J et al: Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility. *Lancet* **1**:1107-1109, 1980
5. Hung S et al: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. *Pharmacogenet Genomics* **16**:297-306, 2006
6. Dainichi T et al: Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: What causes the diversity. *Dermatology* **215**:86-88, 2007
7. Tozzi V: Pharmacogenetics of antiretrovirals. *Antiviral Res* **85**:190-200, 2010
8. Uetrecht J: Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? *Curr Drug Metab* **1**:133-141, 2000
9. Shear N, Spielberg S: Anticonvulsant hypersensitivity syndrome, in vitro assessment of risk. *J Clin Invest* **82**:1826-1832, 1988
10. Seishima M et al: Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. *Br J Dermatol* **155**:344-349, 2006
11. Walsh SA, Creamer D: Drug reaction with eosinophilia and systemic symptoms (DRESS): A clinical update and review of current thinking. *Clin Exp Derm* **36**:6-11, 2011
12. Sullivan J, Shear N: What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions? *Br J Dermatol* **142**:205, 2000
13. Bastuji-Garin S et al: SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. *J Invest Dermatol* **115**:149, 2000
14. Khan D, Solensky R: Drug allergy. *J Allergy Clin Immunol* **125**:S126-S137, 2010
15. Valeyrie-Allanore L, Sassolas B, Roujeau J: Drug-induced skin, nail and hair disorders. *Drug Safety* **30**:1011-1030, 2007
16. Schnyder B, Pichler W: Mechanisms of drug-induced allergy. *Mayo Clin Proc* **84**:268-272, 2009
17. Kerns D, Shira J, Go S: Ampicillin rash in children. *Am J Dis Child* **125**:187-190, 1973
18. Gupta A et al: Drug-induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. *Clin Pharmacol Ther* **51**:56-67, 1992
19. Castrejon J et al: Stimulation of human T cells with sulfonamides and sulfonamide metabolites. *J Allergy Clin Immunol* **125**:411-418, 2010
20. Knowles S, Shapiro L, Shear N: Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of "sulfa" allergy. *Drug Safety* **24**:239-247, 2001
21. Chiou C et al: Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: A study of 30 cases in Taiwan. *J Eur Acad Dermatol Venereol* **22**:1044-1049, 2008
22. Tassaneeyakul W et al: Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. *Pharmacogenet Genomics* **19**:704-709, 2009
23. Kearns G et al: Serum sickness-like reactions to cefaclor: Role of hepatic metabolism and individual susceptibility. *J Pediatr* **125**:805-811, 1994
24. Todd D, Helfgott S: Serum sickness following treatment with rituximab. *J Rheumatol* **34**:430-433, 2007
25. Gamarra R et al: Serum sickness-like reactions in patients receiving intravenous infliximab. *J Emerg Med* **30**:41-44, 2006
26. Remmer H, Falk W: Successful treatment of lithium-induced acne. *J Clin Psychiatry* **47**:48, 1986

27. Cowen E: Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy. *J Am Acad Dermatol* **56**:514-517, 2007
28. Su X et al: Risk of high-grade skin rash in cancer patients treated with cetuximab: An antibody against epidermal growth factor receptor: Systemic review and meta-analysis. *Oncology* **77**:124-133, 2009
29. Guevara-Gutierrez E et al: Acute generalized exanthematous pustulosis: Report of 12 cases and literature review. *Int J Dermatol* **48**:253-258, 2009
30. Britschgi M, Pichler W: Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. *Curr Opin Allergy Clin Immunol* **2**:325-331, 2002
31. Lang B, Finlayson L: Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. *J Pediatr* **124**:639-642, 1994
32. Tolland J, McKeown P, Corbett J: Voriconazole-induced pseudoporphyria. *Photodermatol Photoimmunol Photomed* **23**:29-31, 2007
33. LaDuca J, Bouman P, Gaspari A: Nonsteroidal anti-inflammatory drug-induced pseudoporphyria: A case series. *J Cutan Med Surg* **6**:320-326, 2002
34. Primka E et al: Amiodarone-induced linear IgA disease. *J Am Acad Dermatol* **31**:809-811, 1994
35. Panasiti V et al: Amoxicillin-clavulanic acid-induced linear immunoglobulin A bullous dermatosis: Case report and review of the literature. *Int J Dermatol* **48**:1006-1110, 2009
36. Ruocco V, Sacerdoti G: Pemphigus and bullous pemphigoid due to drugs. *Int J Dermatol* **30**:307-312, 1991
37. Lee J, Downham T: Furosemide-induced bullous pemphigoid: Case report and review of literature. *J Drugs Dermatol* **5**:562-564, 2006
38. Paquet P, Pierard G: New insights in toxic epidermal necrolysis (Lyell's syndrome): Clinical considerations, pathobiology and targeted treatments revisited. *Drug Safety* **33**:189-212, 2010
39. Mockenhaupt M: Severe drug-induced skin reactions: Clinical pattern, diagnostics and therapy. *J Dtsch Dermatol Ges* **7**:142-160, 2009
40. Tripathi J et al: Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: A total series of 67 cases. *Allergy Asthma Proc* **21**:101-105, 2000
41. Murphy J, Purdue G, Hunt J: Toxic epidermal necrolysis. *Burn Care Rehabil* **18**:417-420, 1997
42. Schneck J et al: Effects of treatments of the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR study. *J Am Acad Dermatol* **58**:33-40, 2008
43. Arevalo J et al: Treatment of toxic epidermal necrolysis with cyclosporin A. *J Trauma* **48**:473-478, 2000
44. Barbaud A et al: Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. *Contact Dermatitis* **45**:321-328, 2001
45. Ozkaya E: Fixed drug eruption: State of the art. *J Drugs Dermatol* **6**:181-188, 2008
46. Nazarian R et al: Warfarin-induced skin necrosis. *J Am Acad Dermatol* **61**:325-332, 2009
47. Bircher A et al: Hypersensitivity reactions to anticoagulant drugs: Diagnosis and management options. *Allergy* **61**:1432-1440, 2006
48. Asarch A et al: Lichen planus-like eruptions: An emerging side effect of tumor necrosis factor-alpha antagonists. *J Am Acad Dermatol* **61**:104-111, 2009
49. Kerbleski J, Gottlieb A: Dermatological complications and safety of anti-TNF treatments. *Gut* **58**:1033-1039, 2009
50. Halevy S, Shai A: Lichenoid drug eruptions. *J Am Acad Dermatol* **29**:249-255, 1993
51. Albrecht J, Fine L, Piette W: Drug-associated lymphoma and pseudolymphoma: Recognition and management. *Dermatol Clin* **25**:233-244, 2007
52. Scheinfeld N: Impact of phenytoin therapy on the skin and skin disease. *Expert Opin Drug Saf* **3**:655-665, 2004
53. Justiniano H, Berlingeri-Ramos A, Sanchez J: Patter analysis of drug-induced skin diseases. *Am J Dermatopathol* **30**:352-369, 2008
54. Antonov D et al: Drug-induced lupus erythematosus. *Clin Dermatol* **22**:157-166, 2004
55. Dunphy J et al: Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. *Br J Dermatol* **142**:461-467, 2000
56. Rubin R: Drug-induced lupus. *Toxicology* **209**:135-147, 2005
57. Sarzi-Puttini P et al: Drug-induced lupus erythematosus. *Autoimmunity* **38**:507-518, 2005
58. Marzano A, Vezzoli P, Crosti C: Drug-induced lupus: An update on its dermatologic aspects. *Lupus* **18**:935-940, 2009

59. Auquier-Dunant A et al: Correlations between clinical patterns and causes of erythema multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. *Arch Dermatol* **138**:1019-1024, 2002
60. Neuman M, Malkiewicz I, Shear N: A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. *Clin Biochem* **33**:517-524, 2000
61. Barbaud A: Drug patch testing in systemic cutaneous drug allergy. *Toxicology* **209**:209-216, 2005
62. Shear N et al: A review of drug patch testing and implications for HIV clinicians. *AIDS* **22**:1-9, 2008
63. Drake L et al: Guidelines of care for cutaneous adverse drug reactions. *J Am Acad Dermatol* **35**:458-461, 1996
64. Brennan P et al: Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. *J Allergy Clin Immunol* **124**:1259-1266, 2009